Subcutaneous rituximab for autoimmune bullous diseases

2021 ◽  
Author(s):  
C. Riquelme‐Mc Loughlin ◽  
P. Iranzo
Keyword(s):  
Autoimmune Bullous Diseases ◽  
Bullous Diseases

Autoimmune bullous diseases associations

2012 ◽  
Vol 30 (1) ◽  
pp. 17-33 ◽  
Author(s):  
Suzana Ljubojevic ◽  
Jasna Lipozenčić
Keyword(s):  
Autoimmune Bullous Diseases ◽  
Bullous Diseases

scholarly journals Autoimmune bullous diseases in pregnancy: clinical and epidemiological characteristics and therapeutic approach

2021 ◽  
Author(s):  
Patrícia Penha Silveira Fagundes ◽  
Claudia Giuli Santi ◽  
Celina Wakisaka Maruta ◽  
Denise Miyamoto ◽  
Valeria Aoki
Keyword(s):  
Therapeutic Approach ◽  
Autoimmune Bullous Diseases ◽  
Bullous Diseases ◽  
Epidemiological Characteristics ◽  
In Pregnancy

scholarly journals Milestones in Personalized Medicine in Pemphigus and Pemphigoid

2021 ◽  
Vol 11 ◽  
Author(s):  
Katja Bieber ◽  
Khalaf Kridin ◽  
Shirin Emtenani ◽  
Katharina Boch ◽  
Enno Schmidt ◽  
...  
Keyword(s):  
Personalized Medicine ◽  
Hematological Malignancies ◽  
Clinical Observation ◽  
Medical Model ◽  
Medical Decisions ◽  
Autoimmune Bullous Diseases ◽  
Car T ◽  
Bullous Diseases ◽  
The Individual ◽  
Autoimmune Pathogenesis

Pemphigus and pemphigoid diseases are autoimmune bullous diseases characterized and caused by autoantibodies targeting adhesion molecules in the skin and/or mucous membranes. Personalized medicine is a new medical model that separates patients into different groups and aims to tailor medical decisions, practices, and interventions based on the individual patient`s predicted response or risk factors. An important milestone in personalized medicine in pemphigus and pemphigoid was achieved by verifying the autoimmune pathogenesis underlying these diseases, as well as by identifying and cloning several pemphigus/pemphigoid autoantigens. The latter has become the basis of the current, molecular-based diagnosis that allows the differentiation of about a dozen pemphigus and pemphigoid entities. The importance of autoantigen-identification in pemphigus/pemphigoid is further highlighted by the emergence of autoantigen-specific B cell depleting strategies. To achieve this goal, the chimeric antigen receptor (CAR) T cell technology, which is used for the treatment of certain hematological malignancies, was adopted, by generating chimeric autoantigen receptor (CAAR) T cells. In addition to these more basic science-driven milestones in personalized medicine in pemphigus and pemphigoid, careful clinical observation and epidemiology are again contributing to personalized medicine. The identification of clearly distinct clinical phenotypes in pemphigoid like the non-inflammatory and gliptin-associated bullous pemphigoid embodies a prominent instance of the latter. We here review these exciting developments in basic, translational, clinical, and epidemiological research in pemphigus and pemphigoid. Overall, we hereby aim to attract more researchers and clinicians to this highly interesting and dynamic field of research.

Induced autoimmune bullous diseases

2017 ◽  
Vol 176 (2) ◽  
pp. 304-305 ◽  
Author(s):  
T. Hashimoto
Keyword(s):  
Autoimmune Bullous Diseases ◽  
Bullous Diseases
Sign in / Sign up

Export Citation Format

Share Document